Registered Zambia · ZAMRA

Venosmil

Hidrosmin 200 mg

ZAMRA-HM-25-180 Capsule Gelatin 200 mg

What it does

Hidrosmin is a medication that helps improve blood flow and reduce swelling in the legs.

Commonly used for: chronic venous insufficiency, varicose veins, swelling in the legs

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
ZAMRA-HM-25-180
Registration date
2025-06-16
Expiry date
2030-06-15
Status
Registered/Compliant
Active ingredient
Hidrosmin 200 mg
Dosage form
Capsule Gelatin
Strength
200 mg
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Faes Farma
Applicant / LTR
FAES FARMA S.A.
Country of origin
Spain
Manufacturer location
Planta 5°, Edificio 2, Parque Empresarial Cristalia, C. Vía de los Poblados, 3, Hortaleza, 28033 Madrid, Spain

Source: Zambia Medicines Regulatory Authority · fetched 2026-03-12 00:07:19 · updated 2026-09-17 03:34:48

Disclaimer: This information is sourced from Zambia Medicines Regulatory Authority (Zambia). Always consult a qualified healthcare professional before using any medication.

About this medicine

Hidrosmin is a medication that helps improve blood flow and reduce swelling in the legs.

What it treats

  • chronic venous insufficiency
  • varicose veins
  • swelling in the legs

How it works

Hidrosmin works by strengthening the blood vessels and improving circulation, which helps to relieve discomfort and swelling.

Who it's for

It is suitable for adults who experience symptoms related to poor blood flow in the legs.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: hidrosmin

BNF-referenced

Hidrosmin is a flavonoid compound, primarily derived from the Dioscorea species, known for its venotonic properties. It is utilized in the treatment of chronic venous insufficiency, hemorrhoids, and other vascular disorders due to its ability to improve venous tone and reduce capillary permeability.

Indications

  • Chronic venous insufficiency
  • Hemorrhoids
  • Varicose veins
  • Lymphedema

Dosage

Children: Paediatric dosing information for hidrosmin is not readily available; therefore, it is recommended to consult the BNF for Children or a healthcare professional for appropriate dosing in children.

Adults: For adults, the typical dosage of hidrosmin is 500 mg to 1000 mg taken orally, usually divided into two or three doses per day. It is advisable to refer to specific guidelines or the BNF for further details regarding dosing adjustments based on individual patient needs.

Mechanism of action

Hidrosmin exerts a venotonic effect by enhancing venous tone, which is mediated through a combination of increased venous return and reduced venous distensibility. This is thought to be due to its action on the vascular smooth muscle, promoting contraction and thereby improving venous drainage. Additionally, it may decrease capillary permeability and inhibit inflammatory mediators, contributing to its effectiveness in venous disorders.

Pharmacodynamics

Pharmacodynamically, hidrosmin improves microcirculation and reduces venous stasis, which can alleviate symptoms associated with venous insufficiency such as pain, swelling, and heaviness in the legs. Its anti-inflammatory properties may also play a role in reducing discomfort associated with hemorrhoids and other inflammatory vascular conditions.

Pharmacokinetics

Hidrosmin is well absorbed after oral administration, with peak plasma concentrations typically occurring within 1-2 hours. It undergoes extensive hepatic metabolism, resulting in several metabolites that may also contribute to its therapeutic effects. The elimination half-life is approximately 4-6 hours, and it is primarily excreted through the urine.

Pregnancy

There is limited data on the use of hidrosmin during pregnancy. It should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

There is insufficient information on the excretion of hidrosmin in human milk. Caution should be exercised when administering to breastfeeding women.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: hidrosmin

PubChem CID 3087722

Molecular formula: C30H36O16

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.